Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
IPO Year: 2018
Exchange: NASDAQ
Website: neurostar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | Outperform → Mkt Perform | William Blair | |
| 10/14/2021 | $18.00 → $12.00 | Market Outperform | JMP Securities |
| 10/13/2021 | Outperform → Mkt Perform | William Blair | |
| 10/13/2021 | Buy → Neutral | BTIG |
SD - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
10-Q - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
DEF 14A - Neuronetics, Inc. (0001227636) (Filer)
10-K - Neuronetics, Inc. (0001227636) (Filer)
PRE 14A - Neuronetics, Inc. (0001227636) (Filer)
8-K/A - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)